Shares of ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) fell 3.8% during trading on Monday . The stock traded as low as C$5.98 and last traded at C$6.00. 19,701 shares changed hands during trading, an increase of 492% from the average session volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Stock Performance
The company has a debt-to-equity ratio of 108.33, a quick ratio of 1.30 and a current ratio of 0.51. The firm has a market cap of C$51.48 million, a P/E ratio of -1.78 and a beta of 1.19. The business has a 50-day simple moving average of C$6.00.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Further Reading
- Five stocks we like better than ProMIS Neurosciences
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- The 3 Best Retail Stocks to Shop for in August
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Which Wall Street Analysts are the Most Accurate?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
